search
Back to results

Characterization of Tissular T Follicular Helper Cells in IgG4-RD (TIFOLH4)

Primary Purpose

Disease Immunoglobulin G4

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
blood sample
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Disease Immunoglobulin G4

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with a diagnosis of disease associated with IgG4
  • Patient signed a consent
  • Patient affiliated to the social security scheme

Exclusion Criteria:

  • Patients with a corticosteroid therapy current or less than 3 months.
  • Patients with an immunosuppressive treatment or being less than 3 months
  • Patients with a biotherapy treatment by ongoing or less 6 months

Sites / Locations

  • Assistance Publique Hôpitaux de Marseille

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

diagnosis of disease associated with IgG4

Arm Description

patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4

Outcomes

Primary Outcome Measures

Location of TFH cells by immunofluorescence technical
Ratio of TFH cell on the number of total T lymphocytes by high power field in confocal microscopy in tissues of patients

Secondary Outcome Measures

Full Information

First Posted
August 16, 2016
Last Updated
October 20, 2016
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT02872441
Brief Title
Characterization of Tissular T Follicular Helper Cells in IgG4-RD
Acronym
TIFOLH4
Official Title
Characterization of Tissular T Follicular Helper Cells in IgG4-RD
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2017 (undefined)
Primary Completion Date
January 2020 (Anticipated)
Study Completion Date
January 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
IgG4-related disease (IgG4-RD) is a recently identified rare disease characterized by inflammatory lesions with polyclonal lymphoplasmocytic infiltrate, with IgG4+ plasma cells predominance, and fibrosis in involved tissues. Despite a preferential involvement of exocrine organs, virtually all tissues can be affected by the disease. Corticosteroids are usually effective in this indication, but with poor tolerance and a high risk of relapse after decrease or withdrawal of this treatment. In this context, identification of new therapeutic targets is a major concern for these patients. Physiopathology of IgG4-RD remains actually unknown. In previous studies, it has been shown that T follicular Helper (Tfh) cells are expanded in the blood of these patients. Tfh cells have an important role in the formation of germinal centers (GCs), and ectopic GCs have been found in tissues of patients with IgG4-RD. Tfh cells have a major role in proliferation and differentiation of B cell compartment. In this context, this population could have an important contribution in the pathophysiology of IgG4-RD and could represent a therapeutic target in this disease. TIFOLH4 study intend to analyze tissue Tfh cells in patients with IgG4-RD at diagnosis. This study is an exploratory prospective multicentric study. Thirty patients with a suspected diagnosis of IgG4-RD, because of 1 or more suggestive organ involved, will be included in the study. A 50 mL blood sample and a biopsy, obtained in the same time of the diagnostic biopsy sample, will be obtained in this study. The results obtained in patients with a confirmed diagnosis of IgG4-RD (" IgG4-RD group ") will be compared to results of patients with another diagnosis (" control group "). Main objective of the study is to show by confocal microscopy an expansion of the number of Tfh cells (CD3+CD4+PD1+ cells) in tissue of IgG4-RD patients compared to controls. Secondary objectives include : tissue analysis of Tfh subsets (Tfh1, Tfh2 and Tfh17) ; tissue analysis of B regulatory cells, T regulatory cells, and T helper cells (Th1, Th2, Th17); correlation between tissue and circulating biomarkers; tissue proteomic analysis; and functional analysis of circulating Tfh cells after sorting of these cells and co-culture tests with autologous naive B cells. All these results will be compared between the " IgG4-RD group " and the " control group ". This study should clarify the role of these Tfh populations in IgG4-RD, identify diagnostic tissue and blood biomarkers, and identify therapeutic targets in these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Disease Immunoglobulin G4

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
diagnosis of disease associated with IgG4
Arm Type
Experimental
Arm Description
patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
Intervention Type
Biological
Intervention Name(s)
blood sample
Intervention Description
One blood sample of 50 milliliter 24 hours after the inclusion
Primary Outcome Measure Information:
Title
Location of TFH cells by immunofluorescence technical
Description
Ratio of TFH cell on the number of total T lymphocytes by high power field in confocal microscopy in tissues of patients
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with a diagnosis of disease associated with IgG4 Patient signed a consent Patient affiliated to the social security scheme Exclusion Criteria: Patients with a corticosteroid therapy current or less than 3 months. Patients with an immunosuppressive treatment or being less than 3 months Patients with a biotherapy treatment by ongoing or less 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mikael EBBO, Doctor
Phone
0491388831
Email
mikael.ebbo@ap-hm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Urielle DESALBRES, Director
Phone
0491382747
Email
drci@ap-hm.fr
Facility Information:
Facility Name
Assistance Publique Hôpitaux de Marseille
City
Marseille
ZIP/Postal Code
13354
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mikael EBBO, Doctor
Phone
0491388831
Email
mikael.ebbo@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Urielle DESALBRES, Director
Phone
0491382747
Email
drci@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Mikael EBBO, Doctor

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Characterization of Tissular T Follicular Helper Cells in IgG4-RD

We'll reach out to this number within 24 hrs